News
- Author:
- Susan London
Publish date: January 13, 2021
The combination of recurrence score and Ki-67 response to a short preoperative course of endocrine therapy identified patients who could potentiall...
News
- Author:
- Susan London
Publish date: January 11, 2021
Prospective, randomized data suggest prophylactic whole-pelvis radiotherapy improves cancer outcomes without much increase in late toxicity.
News
- Author:
- Susan London
Publish date: January 11, 2021
Two 1-week adjuvant radiotherapy regimens for breast cancer are as effective as the standard 3-week regimen, the FAST-Forward trial suggests.
News
- Author:
- Susan London
Publish date: January 6, 2021
Efficacy was poorer in node-positive and high-risk patients.
News
- Author:
- Susan London
Publish date: December 24, 2020
The two strategies – one delivering a boost to the whole tumor and the other delivering a boost only to the highl...
News
- Author:
- Susan London
Publish date: December 23, 2020
Compared with whole-breast irradiation, APBI delivered with 3D-conformal radiotherapy yielded slightly poorer 5-y...
News
- Author:
- Susan London
Publish date: December 11, 2020
Compared with the general population, breast cancer survivors were less likely to conceive and more likely to exp...
News
- Author:
- Susan London
Publish date: December 10, 2020
Adding a boost to the visible tumor on MRI reduced the 5-year risk of biochemical recurrence or death by nearly half, without increasing late toxic...
News
- Author:
- Susan London
Publish date: December 9, 2020
More than 13% of women who underwent a mastectomy with reconstruction became persistent users of opioids and/or sedative-hypnotic drugs thereafter....
News
- Author:
- Susan London
Publish date: December 7, 2020
Superior outcomes with intralesional T-VEC plus surgery persisted at 3 years.
News
- Author:
- Susan London
Publish date: November 25, 2020
Cancer patients treated with immune checkpoint inhibitors are not significantly more likely to develop or die from COVID-19, two studies suggest.
News
- Author:
- Susan London
Publish date: November 25, 2020
Final results of the Neo-C-Nivo trial show a 70% pathologic response rate in patients with high-risk resectable m...
News
- Author:
- Susan London
Publish date: November 20, 2020
More than a third of patients had a CNS response to systemically administered pembrolizumab, including two patients who had long-lived complete res...
News
- Author:
- Susan London
Publish date: November 19, 2020
A nationwide cohort study of more than 14,000 patients finds combination immune checkpoint inhibitor therapy, younger age, and a lung cancer diagno...
News
- Author:
- Susan London
Publish date: November 16, 2020
Patients with high-risk prostate cancer having more positive cores on biopsy or a higher Gleason grade were most likely to experience upstaging fro...
